DOP2011000129A - 1h-imidazol-2-il-piperidin-1-il como inhibidores de cinasa akt y p70 s6 - Google Patents
1h-imidazol-2-il-piperidin-1-il como inhibidores de cinasa akt y p70 s6Info
- Publication number
- DOP2011000129A DOP2011000129A DO2011000129A DO2011000129A DOP2011000129A DO P2011000129 A DOP2011000129 A DO P2011000129A DO 2011000129 A DO2011000129 A DO 2011000129A DO 2011000129 A DO2011000129 A DO 2011000129A DO P2011000129 A DOP2011000129 A DO P2011000129A
- Authority
- DO
- Dominican Republic
- Prior art keywords
- formula
- compounds
- cancer
- present
- kinase inhibitors
- Prior art date
Links
- 229940043355 kinase inhibitor Drugs 0.000 title abstract 2
- 239000003757 phosphotransferase inhibitor Substances 0.000 title abstract 2
- 108010013238 70-kDa Ribosomal Protein S6 Kinases Proteins 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 4
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 abstract 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 abstract 2
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 abstract 2
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 abstract 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 abstract 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 abstract 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 abstract 1
- 206010006187 Breast cancer Diseases 0.000 abstract 1
- 208000026310 Breast neoplasm Diseases 0.000 abstract 1
- 206010009944 Colon cancer Diseases 0.000 abstract 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 abstract 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 206010060862 Prostate cancer Diseases 0.000 abstract 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 201000005202 lung cancer Diseases 0.000 abstract 1
- 208000020816 lung neoplasm Diseases 0.000 abstract 1
- UZWDCWONPYILKI-UHFFFAOYSA-N n-[5-[(4-ethylpiperazin-1-yl)methyl]pyridin-2-yl]-5-fluoro-4-(7-fluoro-2-methyl-3-propan-2-ylbenzimidazol-5-yl)pyrimidin-2-amine Chemical group C1CN(CC)CCN1CC(C=N1)=CC=C1NC1=NC=C(F)C(C=2C=C3N(C(C)C)C(C)=NC3=C(F)C=2)=N1 UZWDCWONPYILKI-UHFFFAOYSA-N 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Neurology (AREA)
- Endocrinology (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Reproductive Health (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurosurgery (AREA)
- Child & Adolescent Psychology (AREA)
- Oncology (AREA)
- Emergency Medicine (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención se refiere a inhibidores de cinasa p70 S6 y AKT de la fórmula: Fórmula I caracterizado porque es [5-(4-etil-piperazin-1-ilmetil)-piridin-2-il]-[5-fluoro-4-(7-fluoro-3-isopropil-2-metil-3H-benzoimidazol-5-il)-pirimidin-2-il]-amina. La presente invención también proporciona composiciones farmacéuticas que comprenden compuestos de Fórmula I, usos de compuestos de Fórmula I y métodos para usar compuestos de Fórmula I. Los compuestos de la presente invención son útiles en el tratamiento de cáncer, particularmente cáncer colorectal, cáncer de mama, cáncer de pulmón, especialmente cáncer de pulmón de células no pequeñas (NSCLC), cáncer de próstata, gioblastoma, linfoma de células del manto (MCL), leucemia mieloide crónica (CML) y leucemia mieloide aguda (AML).
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11327308P | 2008-11-11 | 2008-11-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DOP2011000129A true DOP2011000129A (es) | 2016-02-29 |
Family
ID=41402451
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DO2011000129A DOP2011000129A (es) | 2008-11-11 | 2011-05-09 | 1h-imidazol-2-il-piperidin-1-il como inhibidores de cinasa akt y p70 s6 |
Country Status (36)
| Country | Link |
|---|---|
| US (1) | US8148387B2 (es) |
| EP (1) | EP2358710B1 (es) |
| JP (1) | JP5432275B2 (es) |
| KR (1) | KR101334460B1 (es) |
| CN (1) | CN102216302B (es) |
| AR (1) | AR074072A1 (es) |
| AU (1) | AU2009314324B2 (es) |
| BR (1) | BRPI0921916A2 (es) |
| CA (1) | CA2743019C (es) |
| CO (1) | CO6382114A2 (es) |
| CR (1) | CR20110240A (es) |
| CY (1) | CY1113409T1 (es) |
| DK (1) | DK2358710T3 (es) |
| DO (1) | DOP2011000129A (es) |
| EA (1) | EA018947B1 (es) |
| EC (1) | ECSP11011048A (es) |
| ES (1) | ES2391704T3 (es) |
| HN (1) | HN2011001247A (es) |
| HR (1) | HRP20120738T1 (es) |
| IL (1) | IL211940A (es) |
| JO (1) | JO2822B1 (es) |
| MA (1) | MA32776B1 (es) |
| MX (1) | MX2011005000A (es) |
| MY (1) | MY161461A (es) |
| NZ (1) | NZ592062A (es) |
| PA (1) | PA8846901A1 (es) |
| PE (1) | PE20110807A1 (es) |
| PL (1) | PL2358710T3 (es) |
| PT (1) | PT2358710E (es) |
| RS (1) | RS52520B (es) |
| SI (1) | SI2358710T1 (es) |
| TN (1) | TN2011000207A1 (es) |
| TW (1) | TWI422587B (es) |
| UA (1) | UA100190C2 (es) |
| WO (1) | WO2010056563A1 (es) |
| ZA (1) | ZA201102549B (es) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ597579A (en) | 2009-07-02 | 2013-06-28 | Sanofi Sa | Novel (6-oxo-1, 6-dihydro-pyrimidin-2-yl)-amide derivatives, preparation thereof, and pharmaceutical use thereof as akt(pkb) phosphorylation inhibitors |
| AU2010310786B2 (en) * | 2009-10-23 | 2014-03-27 | Eli Lilly And Company | AKT inhibitors |
| EA024890B1 (ru) | 2011-04-07 | 2016-10-31 | Байер Интеллектчуал Проперти Гмбх | Имидазопиридазины в качестве ингибиторов akt киназы |
| EP2730575B1 (en) * | 2011-07-09 | 2015-09-16 | Xuanzhu Pharma Co., Ltd. | Crystal form i of salt of dipeptidyl peptidase-iv inhibitor and preparation method and use thereof |
| SG2014009260A (en) | 2011-09-12 | 2014-09-26 | Merck Patent Gmbh | Aminopyrimidine derivatives for use as modulators of kinase activity |
| SI2755965T1 (sl) | 2011-09-12 | 2017-12-29 | Merck Patent Gmbh | Novi imidazolni amidi kot modulatorji kinazne aktivnosti |
| ES2807539T3 (es) * | 2012-11-16 | 2021-02-23 | Merck Patent Gmbh | Derivados de imidazol-piperidinilo como moduladores de la actividad de quinasa |
| JP6386467B2 (ja) * | 2012-11-16 | 2018-09-05 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ | キナーゼ活性のモジュレーターとしての新規複素環式誘導体 |
| SG11201505999VA (en) * | 2013-03-11 | 2015-08-28 | Merck Patent Gmbh | 6-[4-(1 h-imidazol-2-yl)piperidin-1 -yl]pyrimidin-4-amine derivatives as modulators of kinase activity |
| CN105980375A (zh) * | 2014-02-11 | 2016-09-28 | 默克专利有限公司 | 用作激酶活性调节剂的嘧啶咪唑胺 |
| TW201718574A (zh) | 2015-08-12 | 2017-06-01 | 美國禮來大藥廠 | Ｃｇｒｐ受體拮抗劑 |
| RU2713181C1 (ru) * | 2016-05-20 | 2020-02-04 | Тайхо Фармасьютикал Ко., Лтд. | Новое производное 5h-пирроло[2,3-d]пиримидин-6(7h)-она |
| CN118530260A (zh) | 2020-03-17 | 2024-08-23 | 江苏恒瑞医药股份有限公司 | 稠合二环类衍生物、其制备方法及其在医药上的应用 |
| CN113444110B (zh) * | 2020-03-25 | 2023-05-12 | 江苏恒瑞医药股份有限公司 | 四氢吡咯并吡唑类衍生物、其制备方法及其在医药上的应用 |
| CA3231865A1 (en) | 2021-09-17 | 2023-03-23 | Tingting SHANG | Fused bicyclic derivative, pharmaceutically acceptable salt, crystal form thereof and preparation method therefor |
| MA71401A (fr) * | 2022-07-05 | 2025-04-30 | Taiho Pharmaceutical Co., Ltd. | 5h-pyrrolo[2,3-d]pyrimidine-6(7h)-one, et cristaux de sel de celui-ci |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005117909A2 (en) | 2004-04-23 | 2005-12-15 | Exelixis, Inc. | Kinase modulators and methods of use |
| MY179032A (en) | 2004-10-25 | 2020-10-26 | Cancer Research Tech Ltd | Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors |
| US7994172B2 (en) | 2004-12-28 | 2011-08-09 | Exelixis, Inc. | [1H-pyrazolo[3, 4-D]pyrimidin-4-yl]-piperidine or -piperazine compounds as serine-theoronine kinase modulators (P70s6k, Atk1 and Atk2) for the treatment of immunological, inflammatory and proliferative diseases |
| WO2006091450A1 (en) * | 2005-02-18 | 2006-08-31 | Lexicon Genetics Incorporated | 4-piperidin-1-yl-7h-pyrrolo[2,3-d]pyrimidine compounds |
| WO2007003960A1 (en) | 2005-06-30 | 2007-01-11 | Prosidion Limited | Gpcr agonists |
| JP5606734B2 (ja) | 2006-04-25 | 2014-10-15 | アステックス、セラピューティックス、リミテッド | 医薬化合物 |
| US20090082370A1 (en) | 2006-04-25 | 2009-03-26 | Neil Thomas Thompson | Pharmaceutical Combinations of PK Inhibitors and Other Active Agents |
| WO2008012635A2 (en) | 2006-07-26 | 2008-01-31 | Pfizer Products Inc. | Amine derivatives useful as anticancer agents |
| AR064416A1 (es) * | 2006-12-21 | 2009-04-01 | Cancer Rec Tech Ltd | Derivados de purina, piridina y pirimidina condensadas con heterociclos, moduladores de pka y/o pkb, composiciones farmaceuticas que los contienen, y usos para el tratamiento de enfermedades hiperproliferativas. |
| UA99284C2 (ru) | 2007-05-11 | 2012-08-10 | Елі Ліллі Енд Компані | ИНГИБИТОРЫ р70 S6-КИНАЗЫ |
-
2009
- 2009-10-28 AR ARP090104158A patent/AR074072A1/es unknown
- 2009-10-29 TW TW098136731A patent/TWI422587B/zh not_active IP Right Cessation
- 2009-10-29 PA PA20098846901A patent/PA8846901A1/es unknown
- 2009-10-29 JO JO2009400A patent/JO2822B1/en active
- 2009-11-03 PL PL09744896T patent/PL2358710T3/pl unknown
- 2009-11-03 PE PE2011001018A patent/PE20110807A1/es not_active Application Discontinuation
- 2009-11-03 MY MYPI2011002030A patent/MY161461A/en unknown
- 2009-11-03 JP JP2011536383A patent/JP5432275B2/ja active Active
- 2009-11-03 PT PT09744896T patent/PT2358710E/pt unknown
- 2009-11-03 RS RS20120443A patent/RS52520B/sr unknown
- 2009-11-03 BR BRPI0921916A patent/BRPI0921916A2/pt not_active IP Right Cessation
- 2009-11-03 NZ NZ592062A patent/NZ592062A/xx not_active IP Right Cessation
- 2009-11-03 MX MX2011005000A patent/MX2011005000A/es active IP Right Grant
- 2009-11-03 EP EP09744896A patent/EP2358710B1/en active Active
- 2009-11-03 UA UAA201105367A patent/UA100190C2/ru unknown
- 2009-11-03 CN CN2009801449532A patent/CN102216302B/zh active Active
- 2009-11-03 ES ES09744896T patent/ES2391704T3/es active Active
- 2009-11-03 HR HRP20120738AT patent/HRP20120738T1/hr unknown
- 2009-11-03 US US12/611,139 patent/US8148387B2/en active Active
- 2009-11-03 SI SI200930348T patent/SI2358710T1/sl unknown
- 2009-11-03 DK DK09744896.3T patent/DK2358710T3/da active
- 2009-11-03 WO PCT/US2009/063020 patent/WO2010056563A1/en not_active Ceased
- 2009-11-03 EA EA201170680A patent/EA018947B1/ru not_active IP Right Cessation
- 2009-11-03 KR KR1020117010569A patent/KR101334460B1/ko not_active Expired - Fee Related
- 2009-11-03 AU AU2009314324A patent/AU2009314324B2/en not_active Ceased
- 2009-11-03 CA CA2743019A patent/CA2743019C/en not_active Expired - Fee Related
-
2011
- 2011-03-24 IL IL211940A patent/IL211940A/en not_active IP Right Cessation
- 2011-04-06 ZA ZA2011/02549A patent/ZA201102549B/en unknown
- 2011-04-25 TN TN2011000207A patent/TN2011000207A1/fr unknown
- 2011-05-03 HN HN2011001247A patent/HN2011001247A/es unknown
- 2011-05-06 CR CR20110240A patent/CR20110240A/es unknown
- 2011-05-09 MA MA33822A patent/MA32776B1/fr unknown
- 2011-05-09 DO DO2011000129A patent/DOP2011000129A/es unknown
- 2011-05-11 EC EC2011011048A patent/ECSP11011048A/es unknown
- 2011-05-12 CO CO11058555A patent/CO6382114A2/es active IP Right Grant
-
2012
- 2012-10-05 CY CY20121100928T patent/CY1113409T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20090156A1 (es) | Nuevas pirazolopirimidinas como inhibidores de quinasas dependientes de ciclinas | |
| MX2010003668A (es) | Derivados de purina sustituidas con primidina. | |
| MX2022002581A (es) | Compuestos de benzimidazol como inhibidores de c-kit. | |
| PE20070496A1 (es) | Compuestos derivados de pirazolopirimidinas como inhibidores de quinasas dependientes de ciclina | |
| PE20141381A1 (es) | Terapia de combinacion que comprende un inhibidor de cdk4/6 y un inhibidor de pi3k para el uso en el tratamiento de cancer | |
| MX353308B (es) | Derivados fosforosos como inhibidores de cinasa. | |
| CU20120042A7 (es) | (heteroarilmetil)tiohidantoínas sustituidas como drogas anticáncer | |
| JO3073B1 (ar) | مثبطات ثنائية ملتحمة ثلاثية الحلقة ل cdk 4/6 و flt3 | |
| MX385778B (es) | Uso de dianhidrogalactitol y análogos o derivados del mismo para tratar cáncer de células no pequeñas del pulmón y cáncer de ovario. | |
| CL2011000454A1 (es) | Compuestos derivados de picolinamida, inhibidores de quinasa pim, asociada a tumorigenesis; composicion farmaceutica que los comprende; y su uso en el tratamiento del cancer. | |
| CR10995A (es) | Inhibidores de la actividad de akt | |
| CR20140378A (es) | Derivados de pirido[2,3-d] pirimidina sustituidos con 2-amino, 6-fenilo útiles como inhibidores de cinasa raf | |
| NZ620000A (en) | Prodrug forms of kinase inhibitors and their use in cancer therapy | |
| CO6771441A2 (es) | Compuestos de triazolopiridina como inhibidores de cinasa pim | |
| CL2008003873A1 (es) | Compuestos derivados de benzofuropirimidinona sustituidos, inhibidores de proteinas quinasas; composicion farmaceutica que comprende a uno de los compuestos; metodo para inhibir in vitro proteinas quinasa (pim, cdc7,ck2); y uso de los compuestos en la preparacion de medicamentos para el tratamiento del cancer | |
| MX2014002683A (es) | Derivados de benzonitrilo como inhibidores de cinasa. | |
| NI201000002A (es) | Derivados de morfolino pirimidina utilizados en enfermedades relacionadas con mtor quinasa y/o p13k. | |
| MY163477A (en) | Pyrimidinyl-pyridazinone derivatives | |
| WO2012016133A3 (en) | Ros1 kinase inhibitors for the treatment of glioblastoma and other p53-deficient cancers | |
| MX2014012477A (es) | Inhibidores pirrolopirazona de tanquirasa. | |
| MX336339B (es) | Nuevo uso antitumoral de cabazitaxel. | |
| NZ595602A (en) | Anti-cancer drugs, and uses relating for malignant melanoma and other cancers | |
| UA100540C2 (en) | 2-benzylpyridazinone derivatives as met kinase inhibitors | |
| EA201490472A1 (ru) | Комбинированная терапия рака hsp90-ингибитором и антиметаболитом | |
| CO6382131A2 (es) | Derivados de tieno [3,2-c]piridina como inhibidores de quinasas para el uso en el tratamiento del cáncer |